REGN vs ALNY โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
REGN Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while ALNY counters with relative strength in Valuation. Fundamentally, REGN trades at 14.9x Forward P/E with 30.4% operating margin (+36.3% YoY revenue) versus ALNY at 15.0x Forward P/E and 19.5% operating margin (+16.7% YoY). In options structure, REGN sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against ALNY sits in BREAKDOWN (34th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | REGN Revenue | ALNY Revenue | REGN Op. Margin | ALNY Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $5.15B | $70M | 49.3% | -1087.6% | REGN |
| FY2019 | $6.56B | $220M | 33.7% | -427.5% | REGN |
| FY2020 | $8.50B | $490M | 42.1% | -168.1% | REGN |
| FY2021 | $16.1B | $840M | 55.7% | -83.9% | REGN |
| FY2022 | $12.2B | $1.04B | 38.9% | -75.7% | REGN |
| FY2023 | $13.1B | $1.83B | 30.9% | -15.4% | REGN |
| FY2024 | $14.2B | $2.25B | 28.1% | -7.9% | REGN |
| FY2025 | $14.3B | $3.71B | 24.9% | 13.5% | REGN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | REGN | ALNY | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $97.8B | $20.0B | Larger Scale | REGN |
| Trailing P/E Ratio Valuation | 20.9x | 7.5x | Lower Multiple | ALNY |
| Forward P/E Ratio Valuation | 14.9x | 15.0x | Lower Multiple | REGN |
| Revenue Growth (YoY) Growth | +36.3% | +16.7% | Higher Growth | REGN |
| Operating Margin (TTM) Profitability | 30.4% | 19.5% | Higher Margin | REGN |
| Net Profit Margin Profitability | 28.5% | 52.8% | Higher Margin | ALNY |
| Return on Equity (ROE) Capital Efficiency | 14.9% | 138.1% | Higher ROE | ALNY |
| 52-Week Range Position Momentum | 83% ($592โ$992) | 0% ($147โ$477) | Stronger Trend | REGN |
| Beta / 30D Volatility Risk Regime | 0.32ฮฒ ยท 55% Vol | 0.55ฮฒ ยท 94% Vol | Lower Realized Risk | REGN |
| Unified Institutional Score Composite Signal | 42.6 / 100 (HOLD) | 50.9 / 100 (HOLD) | Higher Composite | ALNY |